FREQUENTLY ASKED
Retatrutide questions, answered from the trial record
Direct answers to the most common questions, with the underlying study cited for each.
Is retatrutide safe?
The honest answer is: not yet fully characterised. Phase 2 and the first two Phase 3 readouts (TRIUMPH-1 and TRIUMPH-4) describe a safety profile in line with the incretin class for gastrointestinal events, plus three signals that warrant continued evaluation: a dose-dependent heart-rate increase of approximately 5-10 bpm in Phase 2 with one severe arrhythmia event reported [4], dysesthesia in 20.9% of the 12 mg group in TRIUMPH-4 versus 0.7% on placebo [13], and adverse-event-driven discontinuation reaching 16-18% at 12 mg [3][13]. The dedicated cardiovascular outcomes trial (TRIUMPH-3) has not yet read out [15]. Long-term safety beyond two years is unknown [17]. The published evidence supports continued investigation; it does not yet support routine clinical use, which is the regulatory question the FDA will eventually decide.
Is retatrutide FDA approved?
No. As of 2026 retatrutide is investigational, not approved by the FDA, the EMA, or any other regulator [15][17]. It is not legally prescribable for any indication outside an enrolled clinical trial. The TRIUMPH Phase 3 program is the evidence base intended to support a regulatory submission; topline results from TRIUMPH-4 (Dec 2025) and TRIUMPH-1 (2026) have been announced, with additional readouts expected through 2026-2027 [10][12][17]. Whether and when the sponsor submits, and whether the FDA approves, are separate questions on a separate timeline.
What are the most common side effects in the trials?
Gastrointestinal events were the most common adverse events across the program — nausea, vomiting, diarrhoea, and constipation, mostly mild-to-moderate and clustered during dose escalation rather than maintenance [3]. They were dose-dependent: in Phase 2, adverse-event-driven discontinuation ranged from 6% at 1 mg to 16% at 12 mg, versus 0% on placebo [3]. In TRIUMPH-4 discontinuation was 12.2% on 9 mg, 18.2% on 12 mg, and 4.0% on placebo [13]. Heart rate increased by approximately 5-10 bpm in Phase 2 and partially declined after week 24 [4]. Dysesthesia (abnormal skin sensation) was reported at 20.9% on 12 mg in TRIUMPH-4 versus 0.7% on placebo [13].
Does retatrutide cause heart problems or arrhythmias?
Phase 2 reported a dose-dependent heart-rate elevation of approximately 5-10 bpm that peaked around week 24 and partially declined thereafter, plus one severe cardiac arrhythmia event (prolonged QT syndrome) [4]. There was no MACE signal versus placebo in Phase 2, but the trial was not powered to detect cardiovascular outcomes. TRIUMPH-3 (NCT05882045) is the dedicated cardiovascular outcomes trial in adults with obesity and established cardiovascular disease; it is the trial that will provide prospective MACE data and as of 2026 it remains active and unreported [15]. Until TRIUMPH-3 reads out, the cardiovascular profile is anchored on the favourable biomarker changes seen in Phase 2 — systolic blood pressure -10.2 mmHg at 12 mg over 48 weeks, triglycerides -40.6%, non-HDL cholesterol -26.9% — and on the heart-rate signal noted above [14].
What is dysesthesia and why does retatrutide cause it?
Dysesthesia is an abnormal cutaneous sensation — tingling, burning, prickling, or numbness — that is not triggered by a normal stimulus. In TRIUMPH-4 it was reported in 20.9% of the 12 mg group versus 0.7% on placebo, and was mostly mild [13]. The mechanism is not yet established. The signal magnitude is higher than what has been reported with other approved incretin therapies and is under further evaluation. Whether it persists, resolves on dose reduction, or relates to rapid weight loss specifically is one of the open questions for the remaining Phase 3 readouts.
How does retatrutide differ from tirzepatide and semaglutide in safety?
Mechanistically, semaglutide is a GLP-1 agonist, tirzepatide is a dual GLP-1/GIP agonist, and retatrutide adds glucagon receptor agonism as a third arm — believed to drive the marked hepatic-fat reduction and the partial offset of resting-energy-expenditure decline [16]. On safety, the gastrointestinal tolerability profile is qualitatively similar across the class — common, dose-dependent, escalation-clustered — though discontinuation rates at the highest retatrutide doses (16-18% on 12 mg) are toward the upper end of what is reported in incretin trials [3][13]. The dysesthesia signal in TRIUMPH-4 is not seen at the same magnitude with semaglutide or tirzepatide and is currently a retatrutide-specific finding under evaluation [13]. Definitive head-to-head safety comparison requires the full TRIUMPH program readouts and the dedicated cardiovascular outcomes trial.
What does the Phase 3 TRIUMPH program show so far about safety?
Two TRIUMPH trials have read out as of 2026. TRIUMPH-4 (Dec 2025) in 445 adults with obesity and knee osteoarthritis reported adverse-event-driven discontinuation of 12.2% (9 mg), 18.2% (12 mg), and 4.0% placebo, dysesthesia of 20.9% (12 mg) versus 0.7% placebo, and a 14 mmHg drop in systolic blood pressure on 12 mg [12][13]. TRIUMPH-1 (2026) in 2,339 adults with obesity without diabetes reported the efficacy topline (28.3% weight loss on 12 mg at 80 weeks) but the full peer-reviewed safety detail is pending [10]. TRIUMPH-3 — the cardiovascular outcomes trial — has not yet reported, and is the trial that will most directly speak to the heart-rate signal first noted in Phase 2 [15].
Is retatrutide safe for people with cardiovascular disease?
There is not yet sufficient evidence to answer this. Adults with established cardiovascular disease are the target population of TRIUMPH-3 (NCT05882045), the trial designed to test this question prospectively [15]. The Phase 2 obesity trial enrolled adults without diabetes and was not powered for cardiovascular outcomes; its biomarker findings (favourable changes in blood pressure, triglycerides, non-HDL cholesterol, apoB) are encouraging but not equivalent to hard outcome data [14]. The heart-rate signal noted in Phase 2 [4] is the principal reason a dedicated cardiovascular outcomes trial was required.
Are the gastrointestinal side effects manageable?
In the trial setting, slow dose escalation improved tolerability compared with fast escalation at the same final dose in the Phase 2 type 2 diabetes trial [5]. The TRIUMPH master protocol uses a 2 → 4 → 6 → 9 → 12 mg stepwise escalation specifically to ease tolerability at the cost of slower time-to-target dose [17]. The events themselves were mostly mild-to-moderate, dose-dependent, and clustered during escalation rather than at maintenance dose [3]. That said, adverse-event-driven discontinuation reached 16-18% at the 12 mg dose [3][13] — which is the practical ceiling on tolerability in the trial population.
What long-term safety data exists?
The longest published follow-up is the TRIUMPH-1 104-week extension, restricted to participants with baseline BMI ≥35; the 12 mg arm averaged 30.3% body-weight loss at two years without an obvious plateau [11]. Beyond approximately two years there is no published human safety or efficacy data for retatrutide [17]. Long-term consequences such as sarcopenia risk in older adults and bone-mineral-density changes at this magnitude of weight loss have not been characterised. No data exist in pregnancy, breastfeeding, or pediatric populations.
Where can I read the underlying trials?
Every claim on this site cites a primary source. The full reference list — Jastreboff 2023 (NEJM), Rosenstock 2023 (Lancet), Sanyal 2024 (Nature Medicine), Urva 2022 (Lancet), Coskun 2025 (Lancet Diabetes & Endocrinology), Li 2024 (Cell Discovery), Katsi 2025 (Biomolecules), the TRIUMPH program ClinicalTrials.gov registrations, and sponsor press releases — is at /references, sortable by year, phase, and indication. Inline citations throughout the site link to PubMed, PMC, or the publishing journal directly.
Is retatrutide on the WADA prohibited list?
Yes, on two grounds. Retatrutide is a peptide hormone acting on incretin and glucagon receptors and falls under WADA Prohibited List Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a metabolic modulator. As an investigational drug that is not approved by any governmental regulatory health authority, it also falls under S0 (Non-Approved Substances). Athletes subject to WADA testing should not use retatrutide.